NRIX Stock Overview
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nurix Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.36 |
| 52 Week High | US$18.12 |
| 52 Week Low | US$4.22 |
| Beta | 2.06 |
| 1 Month Change | -5.07% |
| 3 Month Change | 57.25% |
| 1 Year Change | 28.48% |
| 3 Year Change | -64.42% |
| 5 Year Change | n/a |
| Change since IPO | -34.98% |
Recent News & Updates
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14
Recent updates
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
Jul 07FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
Jun 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Nurix: Advancing Targeted Protein Modulation Therapies
Nov 21Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth
Nov 21We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn
Jul 24Nurix Therapeutics appoints new operations chief
Jun 21Nurix Therapeutics adds Clay Siegall to its board of directors
Jun 01Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Apr 15Shareholder Returns
| NRIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.4% | 0.4% | 1.0% |
| 1Y | 28.5% | 0.9% | 21.9% |
Return vs Industry: NRIX exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: NRIX exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| NRIX volatility | |
|---|---|
| NRIX Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NRIX's share price has been volatile over the past 3 months.
Volatility Over Time: NRIX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 284 | Arthur Sands | www.nurixtx.com |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
Nurix Therapeutics, Inc. Fundamentals Summary
| NRIX fundamental statistics | |
|---|---|
| Market cap | US$733.16m |
| Earnings (TTM) | -US$144.73m |
| Revenue (TTM) | US$80.89m |
9.1x
P/S Ratio-5.1x
P/E RatioIs NRIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRIX income statement (TTM) | |
|---|---|
| Revenue | US$80.89m |
| Cost of Revenue | US$193.34m |
| Gross Profit | -US$112.45m |
| Other Expenses | US$32.28m |
| Earnings | -US$144.73m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.44 |
| Gross Margin | -139.02% |
| Net Profit Margin | -178.93% |
| Debt/Equity Ratio | 0% |
How did NRIX perform over the long term?
See historical performance and comparison